10 Key MedTech Themes for 2025
The MedTech industry has demonstrated remarkable resilience in navigating uncertainty, and 2025 promises to be a pivotal year as the election supercycle concludes and AI regulatory frameworks become clearer.
Vinita Kailasanath</a>, a partner in the Silicon Valley office of <a href=https://medcitynews.com/author/vkailasanathsohyara/"https://www.freshfields.us/">Freshfields, has extensive experience in strategic intellectual property and data-driven transactions in life sciences and technology, and particularly at their intersection. She represents life sciences companies, technology companies, healthcare companies and providers, private equity firms and other investors in connection with the execution of their cutting-edge MedTech and digital health strategies in addition to their other complex licenses and collaborations, strategic investments, and R&D and supply agreements. Ms. Kailasanath has advised clients on transactions involving medical devices (including SaMD), wearables, mobile apps, telemedicine, artificial intelligence/machine learning, software, hardware, pharmaceutical products and biologics. Vinita also routinely advises on the intellectual property aspects of mergers, acquisitions and joint ventures. Vinita avidly tracks trends in MedTech and the associated legal considerations and publishes a quarterly MedTech Update.<br /> <br /> <a href=https://medcitynews.com/author/vkailasanathsohyara/"https://www.linkedin.com/in/shannon-o-hara-a07973bb/">Shannon O’Hara</a> is an Associate in the Life Sciences Transactions team of the Freshfields New York office. She advises companies in the healthcare, pharmaceutical and biotech space on a variety of transactions, including mergers and acquisitions, licensing agreements, commercial agreements and corporate reorganizations." />
The MedTech industry has demonstrated remarkable resilience in navigating uncertainty, and 2025 promises to be a pivotal year as the election supercycle concludes and AI regulatory frameworks become clearer.